Cellyan Biotechnology (HKPD) Receivables (2024 - 2025)
Cellyan Biotechnology (HKPD) reported Receivables of $5.1 million for Q3 2025, up 4.31% year-over-year from $4.9 million in Q3 2024, and up 8.33% quarter-over-quarter from $4.7 million in Q1 2025.
Cellyan Biotechnology (HKPD) Receivables (2024 - 2025) Analysis & Trends
Cellyan Biotechnology (HKPD) has 2 years of Receivables data on file, last reported at $5.1 million in Q3 2025.
- Receivables for Q3 2025 came in at $5.1 million, up 4.31% year-over-year; the trailing twelve-month figure through Sep 2025 was $5.1 million (up 4.31% YoY), and the FY2025 annual result was $4.7 million, up 26.74% from the prior year.
- Receivables climbed to $5.1 million in Q3 2025 per HKPD's latest filing, from $4.7 million in the prior quarter.
- Over five years, Receivables peaked at $5.1 million in Q3 2025 and troughed at $3.7 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Akso Health | 2,315,158.81 Bn | 2,315,158.63 Bn | - | 3.17 Mn |
| 2 | Mckesson | 92.76 Bn | 89.18 Bn | 4.04 Bn | 31.98 Bn |
| 3 | Cencora | 52.82 Bn | 50.83 Bn | 3.59 Bn | 24.89 Bn |
| 4 | Cardinal Health | 52.17 Bn | 48.39 Bn | 2.50 Bn | 13.65 Bn |
| 5 | Henry Schein | 9.19 Bn | 9.71 Bn | 1.07 Bn | 1.75 Bn |
| 6 | Accendra Health | 246.88 Mn | -90.00 Mn | 312.39 Mn | 103.70 Mn |
| 7 | Edap Tms | 161.92 Mn | 146.92 Mn | 8.15 Mn | 20.33 Mn |
| 8 | 111 | 107.47 Mn | 25.61 Mn | 23.58 Mn | 36.61 Mn |
| 9 | Cosmos Health | 9.42 Mn | 7.26 Mn | 1.38 Mn | 18.19 Mn |
| 10 | Cellyan Biotechnology | 5.69 | -2.48 Mn | - | 5.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 5.11 Mn |
| Mar 31, 2025 | 4.71 Mn |
| Sep 30, 2024 | 4.90 Mn |
| Mar 31, 2024 | 3.72 Mn |